Antagonizing inhibition gets NK cells going.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Spatial Clustering of Receptors and Signaling Molecules Regulates NK Cell Response to Peptide Repertoire Changes.Frontiers in immunology · 2019
   Article
2. Balancing natural killer cell activation through paired receptors.Nature reviews. Immunology · 2015
   Review
3. Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94.Proceedings of the National Academy of Sciences of the United States of America · 2013
   Article
4. Controlling natural killer cell responses: integration of signals for activation and inhibition.Annual review of immunology · 2013
   Review
5. Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3.Frontiers in immunology · 2012
   Article

Corrections and comments

• Comment on
  Peptide antagonism as a mechanism for NK cell activation.2010

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as